Systemic sclerosis: Beyond limited and diffuse subsets?

Nature Reviews Rheumatology

Volumn 10, Issue 4, 2014, Pages 200-202

  Varga, John ^a   Hinchcliff, Monique ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; CORTICOSTEROID; DNA DIRECTED RNA POLYMERASE III; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; PM SCL ANTIBODY; RHEUMATOID FACTOR; RNA ANTIBODY; RO ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; GENE; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MYOSITIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; POLR3A GENE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SJOEGREN SYNDROME; SOMATIC MUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ARTICLE; CLASSIFICATION; CONNECTIVE TISSUE DISEASE; PROGNOSIS; TREATMENT OUTCOME;

CONNECTIVE TISSUE DISEASES; HUMANS; PROGNOSIS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84898598276     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.22     Document Type: Short Survey

References (10)

1. LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202-205 (1988).
2. Gliddon, A. E. et al. Antinuclear antibodies and clinical associations in a British cohort with limited cutaneous systemic sclerosis. J. Rheumatol. 38, 702-705 (2011).
3. Meyer, O. C., Fertig, N., Lucas, M., Somogyi, N., & Medsger, T. A. Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J. Rheumatol. 34, 104-109 (2007).
4. Moinzadeh, P. et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-204487.
5. Pakozdi, A. et al. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J. Rheumatol. 38, 2406-2409 (2011).
6. Poormoghim, H., Lucas, M., Fertig, N. & Medsger, T. A. Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 43, 444-451 (2000).
7. Marangoni, R. G. et al. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology (Oxford) 52, 1520-1524 (2013).
8. Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152-157 (2014).
9. Milano, A. et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3, e2696 (2008).
10. Hinchcliff, M. et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J. Invest. Dermatol. 133, 1979-1989 (2013).